Metsera, Inc. (NASDAQ:MTSR - Get Free Report) shares fell 6.9% during trading on Friday . The stock traded as low as $25.47 and last traded at $25.70. 77,054 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 876,134 shares. The stock had previously closed at $27.59.
Wall Street Analyst Weigh In
Several brokerages recently commented on MTSR. Bank of America began coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 target price on the stock. Cantor Fitzgerald began coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an "overweight" rating on the stock. Evercore ISI began coverage on shares of Metsera in a report on Tuesday, February 25th. They issued an "outperform" rating on the stock. Finally, Guggenheim began coverage on shares of Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 target price on the stock.
Read Our Latest Research Report on Metsera
Metsera Trading Down 3.9%
The stock has a 50-day simple moving average of $22.88.
Metsera (NASDAQ:MTSR - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.
Institutional Trading of Metsera
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Alphabet Inc. acquired a new stake in Metsera in the 1st quarter worth $135,059,000. T. Rowe Price Investment Management Inc. acquired a new stake in Metsera in the 1st quarter worth $78,748,000. Wellington Management Group LLP acquired a new stake in shares of Metsera during the 1st quarter valued at about $65,382,000. Alpha Wave Global LP acquired a new stake in shares of Metsera during the 1st quarter valued at about $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in shares of Metsera during the 1st quarter valued at about $42,395,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Further Reading
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
